Terms: = Head and neck cancer AND HSP90AA1, ENSG00000080824, 3320, P07900, LAP2, HSPN, HSPCAL4, HSPCAL1, HSPCA, HSPC1, HSP90N, HSP90A, Hsp90, Hsp89, HSP86, FLJ31884
176 results:
1. hsp90 inhibition suppresses tumor glycolytic flux to potentiate the therapeutic efficacy of radiotherapy for head and neck cancer.
Chen F; Tang C; Yang F; Ekpenyong A; Qin R; Xie J; Momen-Heravi F; Saba NF; Teng Y
Sci Adv; 2024 Feb; 10(8):eadk3663. PubMed ID: 38394204
[TBL] [Abstract] [Full Text] [Related]
2. Amyloid aggregates induced by the p53-R280T mutation lead to loss of p53 function in nasopharyngeal carcinoma.
Li J; Guo M; Chen L; Chen Z; Fu Y; Chen Y
Cell Death Dis; 2024 Jan; 15(1):35. PubMed ID: 38212344
[TBL] [Abstract] [Full Text] [Related]
3. Diagnostic potential of serum hsp90 beta for HNSCC and its therapeutic prognosis after local hyperthermia therapy.
Shetake NG; Kumar A; Huilgol N; Pandey BN
PLoS One; 2023; 18(11):e0281919. PubMed ID: 37943802
[TBL] [Abstract] [Full Text] [Related]
4. PER2 binding to hsp90 enhances immune response against oral squamous cell carcinoma by inhibiting IKK/NF-κB pathway and PD-L1 expression.
Zhang Z; Sun D; Tang H; Ren J; Yin S; Yang K
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37914384
[TBL] [Abstract] [Full Text] [Related]
5. Synergistic effect of hsp90 inhibitor ginkgolic acids C15
Ma H; Huang D; Li B; Ding F; Li H; Wu C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Aug; 48(8):1128-1135. PubMed ID: 37875353
[TBL] [Abstract] [Full Text] [Related]
6. Combination therapy of tyrosine kinase inhibitor sorafenib with the hsp90 inhibitor onalespib as a novel treatment regimen for thyroid cancer.
Mortensen ACL; Berglund H; Hariri M; Papalanis E; Malmberg C; Spiegelberg D
Sci Rep; 2023 Oct; 13(1):16844. PubMed ID: 37803074
[TBL] [Abstract] [Full Text] [Related]
7. Using network pharmacological analysis and molecular docking to investigate the mechanism of action of quercetin's suppression of oral cancer.
Dong H; Li M; Chen H; Tian L; Wei W; Wang S; Cheng G; Liu S
J Cancer Res Clin Oncol; 2023 Nov; 149(16):15055-15067. PubMed ID: 37610675
[TBL] [Abstract] [Full Text] [Related]
8. hsp90aa1 promotes lymphatic metastasis of hypopharyngeal squamous cell carcinoma by regulating epithelial-mesenchymal transition.
Tang F; Li Y; Pan M; Wang Z; Lu T; Liu C; Zhou X; Hu G
Oncol Res; 2023; 31(5):787-803. PubMed ID: 37547757
[TBL] [Abstract] [Full Text] [Related]
9. Control of SOX2 protein stability and tumorigenic activity by E3 ligase CHIP in esophageal cancer cells.
Kang L; Zhang H; Wang Y; Chu M; He J; Xue M; Pan L; Zhang Y; Wang Z; Chen Z; Huang Y; Chen Z; Li E; Li J; Xu L; Zhang R; Wong J
Oncogene; 2023 Jul; 42(30):2315-2328. PubMed ID: 37353616
[TBL] [Abstract] [Full Text] [Related]
10. LncRNA FAS-AS1 upregulated by its genetic variation rs6586163 promotes cell apoptosis in nasopharyngeal carcinoma through regulating mitochondria function and Fas splicing.
Guo Z; Li Z; Zhang M; Bao M; He B; Zhou X
Sci Rep; 2023 May; 13(1):8218. PubMed ID: 37217794
[TBL] [Abstract] [Full Text] [Related]
11. Proteomics Profiling Reveals the Molecular Signatures and Potential Therapeutic Targets of Human Nasopharyngeal Carcinoma.
Fu Y; Liang X; Yang X; Liu J; Huang H; Zhang P; Li S; Zhu D; Zhang Y; Peng F; Chen Y; Chen Z
Mol Cell Proteomics; 2023 Jun; 22(6):100567. PubMed ID: 37172717
[TBL] [Abstract] [Full Text] [Related]
12. Mutant p53 activates hnRNPA2B1-AGAP1-mediated exosome formation to promote esophageal squamous cell carcinoma progression.
Feng R; Yin Y; Wei Y; Li Y; Li L; Zhu R; Yu X; Liu Y; Zhao Y; Liu Z
Cancer Lett; 2023 May; 562():216154. PubMed ID: 37030635
[TBL] [Abstract] [Full Text] [Related]
13. Stress-Inducible SCand Factors Suppress the Stress Response and Are Biomarkers for Enhanced Prognosis in cancers.
Sheta M; Yoshida K; Kanemoto H; Calderwood SK; Eguchi T
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982267
[TBL] [Abstract] [Full Text] [Related]
14. EMT-activated secretory and endocytic vesicular trafficking programs underlie a vulnerability to PI4K2A antagonism in lung cancer.
Tan X; Xiao GY; Wang S; Shi L; Zhao Y; Liu X; Yu J; Russell WK; Creighton CJ; Kurie JM
J Clin Invest; 2023 Apr; 133(7):. PubMed ID: 36757799
[TBL] [Abstract] [Full Text] [Related]
15. Bioinformatics analysis of miRNA and its associated genes to identify potential biomarkers of oral submucous fibrosis and oral malignancy.
Mohanan EM; Jhala D; More CB; Patel AK; Joshi C
Cancer Rep (Hoboken); 2023 Apr; 6(4):e1787. PubMed ID: 36708238
[TBL] [Abstract] [Full Text] [Related]
16. Establishment of esophageal squamous carcinoma cell lines with different invasive metastatic potential and differential gene screening.
Li XJ; Zhang QQ; Li J; Guo Y; Yao JJ; Wen GZ; Zhang ZQ
J Physiol Pharmacol; 2022 Aug; 73(4):. PubMed ID: 36696239
[TBL] [Abstract] [Full Text] [Related]
17. Network Pharmacological Study of Compound Kushen Injection in Esophageal cancer.
Guo D; Jin J; Liu J; Ren M; He Y
Curr Comput Aided Drug Des; 2023; 19(5):367-381. PubMed ID: 36635923
[TBL] [Abstract] [Full Text] [Related]
18. Fisetin, a dietary flavonoid, increases the sensitivity of chemoresistant head and neck carcinoma cells to cisplatin possibly through hsp90aa1/IL-17 pathway.
Ling J; Zhang L; Wang Y; Chang A; Huang Y; Zhao H; Zhuo X
Phytother Res; 2023 May; 37(5):1997-2011. PubMed ID: 36631292
[TBL] [Abstract] [Full Text] [Related]
19. MiR-302c-5p affects the stemness and cisplatin resistance of nasopharyngeal carcinoma cells by regulating hsp90aa1.
Zhou X; Zheng L; Zeng C; Wu Y; Tang X; Zhu Y; Tang S
Anticancer Drugs; 2023 Jan; 34(1):135-143. PubMed ID: 36539366
[TBL] [Abstract] [Full Text] [Related]
20. Role of genetic variations of DNA damage response pathway genes and heat-shock proteins in increased head and neck cancer risk.
Mahjabeen I; Sheshe S; Shakoor T; Hussain MZ; Rizwan M; Mehmood A; Haris MS; Fazal F; Burki A; Kayani MA
Future Oncol; 2022 Oct; 18(31):3519-3535. PubMed ID: 36200797
[TBL] [Abstract] [Full Text] [Related]
[Next]
